DNA/RNA Synthesis Core
The DNA/RNA Synthesis Core provides expertise, consultations and experience in the area of chemical synthesis of RNA/DNA oligonucleotides. These services promote collaborations and enhance scientific productivity of the City of Hope Research Community.
The Core has the ability to support peer-review grants from a variety of Center investigators by providing products that are not commercially available.
The value added of this Core is demonstrated by the active collaborations amongst its staff and research community members; the sharing of instruments, methodologies and scientific insights. The Core supports basic research in cell and Molecular Biology, Immunology, Onco-Immunology, Proteomics and Diagnostics.
Scientific Accomplishments
Since its inception in 1979, the original Synthesis Core has maintained significant impact on the successful execution and completion of a number of research projects. This core has a long history of scientific achievement and innovation. The DNA/RNA Synthesis Laboratory enables customized synthesis and also very complex chemical modification of oligonucleotides, providing a variety of custom oligonucleotides to the research community of City of Hope Cancer Center. The laboratory has pioneered the synthesis of chimeric DNA/RNA/DNA molecules for use as hammerhead ribozymes having enhanced catalytic efficiency. In addition, a variety of labels and linkers, such as chelate DOTA and various fluorophores, can be incorporated into the oligomers. Some of those reagents are commercially available but some have to be synthesized in our laboratory.
DNA/RNA Synthesis Laboratory has successfully synthesized highly modified RNA aptamers that were 120-bases long. Unique technology developed in the Laboratory allows to anneal those aptamers to a variety of siRNAs, creating customized constructs, a new class of potentially ground breaking anti-cancer drugs. Recently Laboratory has perfected the technology of attaching oligonucleotides to the antibodies. It opens new possibilities for the drug delivery and creation of new class of anticancer drugs. As a significant portion of these technologies is developed “in-house” to meet specific research demands, they have been successfully applied to a myriad of Cancer Center projects.
Contact the Team
- CN SNP microarray analysis (single sample or large cohort)
- Consultations and oligo design services in the area of aptamers-siRNA , CpG-dsRNA, CpG-anti-miR, CpG-mimic constructs and other complex oligonucleotides
- Synthesis of large amounts (200mg-500mg) of unique oligoribonuleotides, modified/labeled on base or/and sugar
- Synthesis of large amounts (200mg-500mg) of very pure, highly modified siRNA for animal studies
- Synthesis of large amounts of very pure, highly modified RNA aptamers for animal studies
- Synthesis of conjugates of oligonucleotides with specialized molecules and with other biopolymers, for example: siRNA-aptamer or DNA-peptide or saRNA-antibody
- Synthesis of oligonucleotides with specialized molecules such as DOTA or various dyes
- Synthesis of nucleoside based synthons for the synthesis of modified oligomers
- US Patent: 5766550 Piotr M. Swiderski, BE Kaplan, A single use disposable cartridge used for the storage and delivery of expensive amidites/reagents to the reaction cell of a DNA/RNA synthesizer (1994), issued in 1998.
- US Patent: 6379931 JJ Rossi, Piotr M. Swiderski, Chimeric and non-chimeric comprised of DNA, RNA, modified RNA and propanediols (1998), issued in 2002.
- US Patent: Q Liu, Piotr M. Swiderski, and SS Sommer, “Truncated amplification: a method for high-fidelity template-driven nucleic acid amplification” filled in 2002
- US Patent: M Kortylewski, Piotr M. Swiderski, JJ Rossi, R Jove, H Yu, “Methods and compositions for the treatment of cancer or other diseases,” filled in 2007
- US Patent: JJ Rossi, Piotr M. Swiderski, J Zhou, “Cell-type specific aptamer - siRNA delivery system for HIV-1 therapy (1954-499)” filled in 2009
- US Patent: Kortylewski, Marcin; Swiderski, Piotr “STAT3 INHIBITORS AND USES THEREOF”, filled 2013
- US Patent: Swiderski, Piotr, “Multivalent Oligonucleotide Assembles”. Pub. Date Feb.2, 2017, Pub. No.: US 2017/0029816 A1
- US Patent: Kortylewski, Marcin; Swiderski, Piotr, Immunostimulatory CpG-STAT3 decoy oligodeoxynucleotides for therapy of metastatic cancers (TEC 13-042) (95058-889594)
- US Patent: Herrmann Andreas, Lin Lee, Shively John, Swiderski, Piotr, Yu Hua “Cell Penetrating Conjugates and Methods of Use Thereof” 95058-002701US-900656 filed in 2013
- US Patent: Swiderski, Piotr, Shively John, Rossi John “Bis-specific Conjugates” Filed in February 2017
- US Patent: Kortylewski, Marcin; Swiderski, Piotr; Steven Rosen, OLIGONUCLEOTIDE-BASED PROTEOLYSIS TARGETING CHIMERA AND THE USES THEREOF, filed on June 15, 2018, U.S. Serial No. 62/685,810
- US Patent: Kortylewski, Marcin; Swiderski, Piotr; OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPALIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USESTHEREOF,”
- US Patent: Kortylewski, Swiderski, Marcucci, Zhang, Kuo, COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGONUCLEOTIDE, AND METHODS OF USE THEREOF Nov. 1, 2018
Current pricing can be found on iLab Solutions.
DNA/RNA Synthesis Laboratory is equipped in two fully automated DNA/RNA synthesizers, OligoPilot10+ (GE Healthcare) capable of the synthesis at 100umole scale and FPLC Purifier (GE Healthcare), two prep HPLCs from Gilson and an analytical HPLC from Agilent.
In a given year, City of Hope conducts more than 400 clinical trials enrolling more than 6,000 patients.
Su, Y. L., Wang, X., Mann, M., Adamus, T. P., Wang, D., Moreira, D. F., Zhang, Z., Ouyang, C., He, X., Zhang, B., Swiderski, P. M., Forman, S. J., Baltimore, D., Li, L., Marcucci, G., Boldin, M. P., & Kortylewski, M.
Nuzzo, S., Catuogno, S., Capuozzo, M., Fiorelli, A., Swiderski, P., Boccella, S., de Nigris, F., & Esposito, C. L.
Su, Y. L., Wang, X., Mann, M., Adamus, T. P., Wang, D., Moreira, D. F., Zhang, Z., Ouyang, C., He, X., Zhang, B., Swiderski, P. M., Forman, S. J., Baltimore, D., Li, L., Marcucci, G., Boldin, M. P., & Kortylewski, M.
City of Hope is focused on basic and clinical research in cancer, diabetes and other life-threatening diseases.
